Tafolecimab Biosimilar

Tafolecimab is a fully Human monoclonal antibody biosimilar expressed in CHO cells, targeting PCSK9, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

GPRC5D/CD3 bispecific antibody is used to treat multiple myeloma. The bispecific antibody is generically named tafolecimab. It is constructed using the Duobody technology authorized by Genmab. The heavy chain of the anti-CD3 antibody is introduced into F405L and R409K to construct the double antibody. S228P, F234A, and L235A mutations were also introduced into the IgG4 constant region.

Target	PCSK9
Research Area	Biosimilars
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG2 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life	12 months.
Buffer	0.01 M PBS, pH 7.4.
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 5-10 working days.
Note	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Research Articles on PCSK9

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue